3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Lymphoma, T-Cell, Cutaneous
8
Lymphoma
6
Immunoblastic Lymphadenopathy
6
Mycosis Fungoides
5
Lymphoma, Large-Cell, Anaplastic
5
Sezary Syndrome
4
Subcutaneous panniculitis-like T-cell lymphoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Melanoma
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, T-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Extranodal NK-T-Cell
3
Sarcoma
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Hairy Cell
2
Leukemia, Biphenotypic, Acute
2
Enteropathy-Associated T-Cell Lymphoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Blast Crisis
2
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Interventions
cemiplimab
3
Transdermal Patch
1
Sirolimus
1
Prednisone
1
Everolimus
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cutaneous Squamous Cell Carcinoma
×
Doxorubicin
×
Dermatologic
×
Clear all
NCT05377905
2026-04-09
cSCC
University of Pittsburgh
Phase 1/2
Recruiting
48 enrolled